FIG. 2.

KIM-1, miR-21, -200c, and -423 increase in the longitudinal Cp cohort in patients with and without clinical AKI. Levels of miR-21, -200c, and -423 as well as KIM-1 were measured in urine from patients (n = 108) before (Pre) and on 9 following time points after Cp treatment grouping patients based on their SCr dependent AKI status. Data sets were normalized to UCr, log2 transformed and presented as box plots (median with 25th and 75th percentiles) with 5th and 95th percentile as whiskers. T-test was used for P-value calculation to compare with the group baseline as well as within the two groups: *P < .0014. Broken lines represent the median level before treatment of No AKI developers.